Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by The Chaim Sheba Medical Center
Sponsor:
Information provided by (Responsible Party):
Prof. Doron Gothelf, The Chaim Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00768820
First received: October 7, 2008
Last updated: January 28, 2016
Last verified: January 2016

October 7, 2008
January 28, 2016
May 2001
December 2020   (final data collection date for primary outcome measure)
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00768820 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
Not Provided
Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Velocardiofacial Syndrome
  • Williams Syndrome
  • Fragile X Syndrome
Drug: methylphenidate, fluoxetin, risperidone
first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
Experimental: 1
Intervention: Drug: methylphenidate, fluoxetin, risperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
December 2020
December 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • chromosomal deletion proven by FISH examination

Exclusion Criteria:

Both
Child, Adult, Senior
No
Contact: Doron Gothelf, MD 972-03-5302663 gothelf@post.tau.ac.il
Israel
 
NCT00768820
SCMCI082455CTIL
Yes
Not Provided
Not Provided
Prof. Doron Gothelf, The Chaim Sheba Medical Center
The Chaim Sheba Medical Center
Not Provided
Not Provided
The Chaim Sheba Medical Center
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP